PHOENIX, AZ – June 12, 2025 – nVector, Inc. a leader in innovative solutions for neurodegenerative disease research, proudly announces the launch of its proprietary TDP-43 Assay Diluent, a cutting-edge tool designed to enhance the detection and quantification of TDP-43 protein in biofluids for amyotrophic lateral sclerosis (ALS) research. This novel diluent, optimized for use in electrochemiluminescence immunoassays, promises to revolutionize how researchers’ study TDP-43 proteinopathy, a critical feature present in 97% of ALS cases.
Detailed in the 2025 study, “Development of a Sensitive and Reliable Meso Scale Discovery-Based Electrochemiluminescence Immunoassay to Quantify TDP-43 in Human Biofluids”, nVector’s TDP-43 Assay Diluent is engineered to maximize antibody binding and specificity in complex biological matrices such as plasma and serum. By stabilizing antibodies and TDP-43 protein, the diluent ensures highly reproducible and reliable results, addressing challenges like antibody cross-reactivity and poor specificity that have previously hindered TDP-43 quantification. The optimized protocol employs a sandwich immunoassay configuration using Meso Scale Discovery (MSD) SECTOR Plates, achieving exceptional signal-to-noise ratios through rigorous optimization of wash conditions, incubation times, and temperatures.
This innovative diluent offers ALS researchers’ significant advantages. It enables precise measurement of full-length TDP-43 in human biofluids, providing a non-invasive approach to study TDP-43 pathology, essential for developing biomarkers and therapeutic strategies. Its high sensitivity and specificity minimize background noise, allowing researchers to confidently analyze TDP-43 levels in complex samples. This tool streamlines laboratory workflows, saving time and resources while deepening insights into ALS pathogenesis.
“nVector’s TDP-43 Assay Diluent is a game-changer for ALS research, offering unmatched precision in quantifying TDP-43 in biofluids, which could unlock new pathways for biomarker discovery and therapeutic development,” said Robert Bowser Ph.D., Lead Neuroscientist and Chairman of nVector.
The diluent’s practical benefits have also been lauded in laboratory settings. “The ease of use and robust performance of nVector’s TDP-43 Assay Diluent have significantly improved our lab’s efficiency, allowing us to generate reliable data with confidence,” said Jiyan An, Lab Manager at nVector.
By providing a dependable method to quantify TDP-43, nVector’s assay diluent empowers researchers to explore new frontiers in ALS diagnostics and therapeutics, offering hope to those impacted by this devastating disease. The TDP-43 Assay Diluent is now available for purchase, serving as a vital resource for the global neuroscience community.
About nVector
nVector is a leading biotechnology company committed to advancing research into neurodegenerative diseases. Through innovative tools and services, nVector equips researchers with cutting-edge solutions to address complex challenges in ALS, Alzheimer’s, and other proteinopathies. For more information about nVector’s TDP-43 Assay Diluent, visit https://nvector.com/products-services/tdp-43-assay-diluent/.
Access the research paper at https://pmc.ncbi.nlm.nih.gov/articles/PMC11675039/
Access the Safety Data Sheet at https://nvector.com/wp-content/uploads/2025/05/SDS-Final.pdf.
Contact:
Robert Bowser,
Chairman, Neuroscientist, nVector
Email: Robert. Bowser@nvector.com
Phone: (724) 612-3665
